BioSpace News Archive

Bayer AG and BlueRock Therapeutics announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell platform.

AVEO Oncology reported financial results for the second quarter ended June 30, 2019 and provided a business update.

ArunA Bio, Inc., a leader in the development of neural exosomes for the treatment of neurodegenerative diseases, announced the addition of Tony Townley to its Board of Directors.

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, reported financial results for the second quarter ended June 30, 2019, and provided a business update.

The Tender Offers are being made upon the terms and subject to the conditions set forth in the Offer to Purchase dated August 8, 2019 (as amended or supplemented from time to time, the “Offer to Purchase”), which sets forth a more detailed description of the Tender Offers.

K Health, a digital health company that offers free personalized healthcare, and Health Gorilla, a leader in secure interoperability solutions, announced today a collaboration to power new clinical functionality to improve the primary care experience

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that more than 4,000 people with amyotrophic lateral sclerosis (ALS) in the United States have received treatment with RADICAVA® (edaravone) and over 1,100 healthcare providers have prescribed the therapy to one or more of their ALS patients since it became available in August 2017

International Cardio Corporation (ICC) announced today that it has achieved the first human use milestone of its HIFU Synthesizer™, a therapeutic ultrasound system designed to noninvasively treat vulnerable and occlusive plaques in peripheral arteries.

Physicians’ Education Resource®, a worldwide leading resource for continuing medical education, named public health expert and former commissioner of the Food and Drug Administration Scott Gottlieb, M.D., as the keynote speaker for the 37th Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow®.

Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), named Children’s Hospital of Richmond at VCU (CHoR) the 26th Certified Duchenne Care Center (CDCC).